CG Oncology (CGON) director Leonard Post sells 1,000 shares, receives new options
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
CG Oncology, Inc. director Leonard E. Post reported an exercise-and-sale transaction plus a new option grant. He exercised 1,000 stock options at $0.60 per share and sold 1,000 common shares at $54.50 per share under a pre-arranged Rule 10b5-1 trading plan. He also received a fully vested grant of 9,354 director stock options with a $56.09 exercise price, while another option grant for 9,354 shares vests monthly after June 4, 2026. Following these transactions, he holds 1,000 common shares and 116,077 director stock options.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 1,000 shares ($54,500)
Net Sell
4 txns
Insider
POST LEONARD E
Role
null
Sold
1,000 shs ($55K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Director Stock Option (right to buy) | 1,000 | $0.00 | -- |
| Grant/Award | Director Stock Option (right to buy) | 9,354 | $0.00 | -- |
| Exercise | Common Stock | 1,000 | $0.60 | $600.00 |
| Sale | Common Stock | 1,000 | $54.50 | $55K |
Holdings After Transaction:
Director Stock Option (right to buy) — 116,077 shares (Direct, null);
Common Stock — 1,000 shares (Direct, null)
Footnotes (1)
- The option exercise and sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 5, 2026 Fully vested. 1/12th of the total number of shares of common stock subject to the option vest monthly following June 4, 2026, the date of grant (or, in the event the next annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of this stock option will vest on the date of such annual meeting of the Issuer's stockholders), subject to the Reporting Person's continuous service to the Issuer through each vesting date.
Key Figures
Shares sold: 1,000 shares
Sale price: $54.50/share
Options exercised: 1,000 shares
+5 more
8 metrics
Shares sold
1,000 shares
Common Stock open-market sale at $54.50 on June 4, 2026
Sale price
$54.50/share
Price for 1,000 CG Oncology common shares sold
Options exercised
1,000 shares
Common Stock acquired via option exercise at $0.60
Exercise price
$0.60/share
Strike price for 1,000 options converted to common stock
New option grant
9,354 options
Director Stock Option grant on June 4, 2026
New option strike price
$56.09/share
Exercise price of newly granted director stock options
Options remaining
116,077 options
Director Stock Option holdings following transactions
Option expiration
June 3, 2036
Expiration date for newly granted director stock options
Key Terms
Rule 10b5-1 trading plan, Director Stock Option, Exercise or conversion of derivative security, Grant, award, or other acquisition, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"The option exercise and sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Director Stock Option financial
"Director Stock Option (right to buy)"
Exercise or conversion of derivative security financial
"transaction_code_description": "Exercise or conversion of derivative security"
Grant, award, or other acquisition financial
"transaction_code_description": "Grant, award, or other acquisition"
vesting financial
"1/12th of the total number of shares of common stock subject to the option vest monthly following June 4, 2026"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
What insider transactions did CG Oncology (CGON) director Leonard E. Post report?
Leonard E. Post reported exercising 1,000 stock options and selling 1,000 CG Oncology common shares. He also reported the grant of 9,354 director stock options and continues to hold 1,000 common shares plus 116,077 director stock options after these transactions.
What new CG Oncology (CGON) director stock options did Leonard E. Post receive?
He received a grant of 9,354 director stock options with a $56.09 exercise price. One grant is described as fully vested, while another vests in monthly installments after June 4, 2026, subject to his continued service with CG Oncology.
How many CG Oncology (CGON) securities does Leonard E. Post hold after these transactions?
After the reported transactions, he holds 1,000 CG Oncology common shares directly and 116,077 director stock options. These remaining options provide rights to purchase additional shares at specified exercise prices and future dates, according to the vesting and expiration terms disclosed.
When do Leonard E. Post’s new CG Oncology (CGON) options expire and vest?
The newly granted 9,354 director stock options have an expiration date of June 3, 2036. For one grant, one-twelfth of the total shares vest monthly after June 4, 2026, with any remaining unvested portion vesting at the next annual stockholder meeting if earlier.